273 related articles for article (PubMed ID: 17359484)
1. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds.
Tölle M; Levkau B; Kleuser B; van der Giet M
Eur J Clin Invest; 2007 Mar; 37(3):171-9. PubMed ID: 17359484
[TBL] [Abstract][Full Text] [Related]
2. Relevance and potential of sphingosine-1-phosphate in vascular inflammatory disease.
van der Giet M; Tölle M; Kleuser B
Biol Chem; 2008 Nov; 389(11):1381-90. PubMed ID: 18925828
[TBL] [Abstract][Full Text] [Related]
3. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice.
Keul P; Tölle M; Lucke S; von Wnuck Lipinski K; Heusch G; Schuchardt M; van der Giet M; Levkau B
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):607-13. PubMed ID: 17158351
[TBL] [Abstract][Full Text] [Related]
4. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
Brinkmann V
Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
[TBL] [Abstract][Full Text] [Related]
6. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology.
von Wenckstern H; Zimmermann K; Kleuser B
Arch Immunol Ther Exp (Warsz); 2006; 54(4):239-51. PubMed ID: 16830220
[TBL] [Abstract][Full Text] [Related]
7. FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression.
Krump-Konvalinkova V; Chwalla I; Siess W
Biochem Biophys Res Commun; 2008 Jun; 370(4):603-8. PubMed ID: 18402775
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
Clemens JJ; Davis MD; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878
[TBL] [Abstract][Full Text] [Related]
9. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C
J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465
[TBL] [Abstract][Full Text] [Related]
10. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets.
Huwiler A; Pfeilschifter J
Biochem Pharmacol; 2008 May; 75(10):1893-900. PubMed ID: 18321471
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
LaMontagne K; Littlewood-Evans A; Schnell C; O'Reilly T; Wyder L; Sanchez T; Probst B; Butler J; Wood A; Liau G; Billy E; Theuer A; Hla T; Wood J
Cancer Res; 2006 Jan; 66(1):221-31. PubMed ID: 16397235
[TBL] [Abstract][Full Text] [Related]
12. FTY720 modulates human oligodendrocyte progenitor process extension and survival.
Miron VE; Jung CG; Kim HJ; Kennedy TE; Soliven B; Antel JP
Ann Neurol; 2008 Jan; 63(1):61-71. PubMed ID: 17918267
[TBL] [Abstract][Full Text] [Related]
13. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
14. Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog.
Ushitora Y; Tashiro H; Ogawa T; Tanimoto Y; Kuroda S; Kobayashi T; Miyata Y; Itamoto T; Asahara T; Ohdan H
Transplantation; 2009 Oct; 88(8):980-6. PubMed ID: 19855243
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine-1-phosphate signaling in the cardiovascular system.
Peters SL; Alewijnse AE
Curr Opin Pharmacol; 2007 Apr; 7(2):186-92. PubMed ID: 17280869
[TBL] [Abstract][Full Text] [Related]
16. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
Ter Braak M; Claas RF; Hegen B; Labocha S; Ferreirós N; Pfeilschifter J; Huwiler A; van Echten-Deckert G; Meyer Zu Heringdorf D
Biochem Pharmacol; 2011 Mar; 81(5):617-25. PubMed ID: 21163254
[TBL] [Abstract][Full Text] [Related]
17. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
18. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
19. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis.
Liu HB; Cui NQ; Wang Q; Li DH; Xue XP
Pancreas; 2008 Apr; 36(3):e10-5. PubMed ID: 18362832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
